This research-based project will demonstrate the efficacy of a moderate hypofractionated regimen for the treatment of favorable intermediate-risk prostate cancer. Prostate cancer is a major cause of disease and mortality among men. Research indicates that each year, 1.6 million men are diagnosed with it and 366,000 die from it. Diagnosis is based on rectal examination, serum prostate specific antigen (PSA) measurement, and when essential, transrectal prostate needle biopsy followed by a Gleason score obtained from it. When treating prostate cancer, identifying a Gleason score is the deciding factor in choosing from a wide spectrum of treatment options ranging from supervision to multimodal treatment. Upon completion of essential tests, the primary tumor is assigned a stage based on the American Joint Committee on Cancer’s (AJCC) 8th edition Tumor Node Metastasis (TNM) staging system for prostate cancer and the patient is placed in a risk group. If radiation therapy treatment is required, the patient will undergo a process consisting of a treatment simulation followed by treatment planning. The preferred External Beam Radiation Therapy (EBRT) regimen is moderate hypofractionation. This prospect focuses on a case study of a 54-year-old gentleman who successfully underwent pelvic radiation therapy using hypofractionation doses for the treatment of prostate cancer.
Prostate cancer, hypofractionation, prostate screening
Medicine and Health Sciences
Torres-Teran, Carlos, "Hypofractionation Treatment of Favorable Intermediate-risk Prostate Cancer" (2021). Medical Imaging Senior Posters. 18.